Q3 2021 13F Holders as of 30 Sep 2021
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
4.99M
-
Number of holders
-
108
-
Total 13F shares, excl. options
-
68.7M
-
Shares change
-
-2.42M
-
Total reported value, excl. options
-
$648M
-
Value change
-
-$40.8M
-
Put/Call ratio
-
1.35
-
Number of buys
-
53
-
Number of sells
-
-64
-
Price
-
$9.43
Significant Holders of Mersana Therapeutics, Inc. - Common Stock, par value $0.0001 per share (MRSN) as of Q3 2021
149 filings reported holding MRSN - Mersana Therapeutics, Inc. - Common Stock, par value $0.0001 per share as of Q3 2021.
Mersana Therapeutics, Inc. - Common Stock, par value $0.0001 per share (MRSN) has 108 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 68.7M shares
.
Largest 10 shareholders include BlackRock Inc. (8.81M shares), Avoro Capital Advisors LLC (6.8M shares), WELLINGTON MANAGEMENT GROUP LLP (6.01M shares), Sarissa Capital Management LP (4.3M shares), Bellevue Group AG (4.26M shares), STATE STREET CORP (4.09M shares), Bain Capital Life Sciences Investors, LLC (3.7M shares), VANGUARD GROUP INC (3.68M shares), Rock Springs Capital Management LP (3.02M shares), and ORBIMED ADVISORS LLC (2.89M shares).
This table shows the top 108 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.